http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-081970-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93e8f3f0e161df3d09d4b9a837a21e23 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-429 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-429 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-10 |
| filingDate | 2011-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9785f98ac1d75f14703e04df75e3718c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6254ec3e1f5eecc0bdb742024c5cd07 |
| publicationDate | 2012-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-081970-A1 |
| titleOfInvention | INJECTABLE FORMULATION OF A MACROCICLIC AND LEVAMISOL LACTONE, FORMULATION AND VETERINARY USE |
| abstract | Formulations for controlling parasites comprising a combination of a compound of a macrocyclic lactone and levamisole, wherein levamisole is in the form of particles suspended in a non-aqueous solvent. Claim 1: A formulation of a solution of a macrocyclic lactone characterized in that it comprises Levamisole in the form of particles in a non-aqueous solvent system. Claim 6: The formulation according to claim 1, characterized in that the macrocyclic lactone compound is selected from the group comprising abamectin, doramectin, eprinomectin, ivermectin and moxidectin. Claim 9: The formulation according to claim 1, characterized in that the formulation additionally includes at least one additional drug selected from the group of anthelmintics, dietary supplements, vitamins, minerals. Claim 11: The formulation according to claim 1, characterized in that it comprises: approx. 1.5 to 4% w / v ivermectin, approx. 15 to 18.8% w / v of levamisole, and wherein levamisole is in particles and ivermectin is substantially in a non-aqueous solvent system comprising an oil and an organic solvent. Claim 12: The formulation according to claim 11, characterized in that the oil comprises castor oil and a medium chain triglyceride or a mixture of medium chain triglycerides. Claim 13: The formulation according to claim 11, characterized in that the organic solvent is dimethylacetamide. |
| priorityDate | 2010-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.